HOOKIPA Pharma Inc. (HOOK)

NASDAQ: HOOK · Real-Time Price · USD
2.220
-0.190 (-7.88%)
Dec 11, 2024, 4:00 PM EST - Market closed
-7.88%
Market Cap 26.76M
Revenue (ttm) 50.00M
Net Income (ttm) -43.37M
Shares Out 12.05M
EPS (ttm) -3.55
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 66,717
Open 2.350
Previous Close 2.410
Day's Range 2.155 - 2.430
52-Week Range 2.080 - 11.300
Beta 0.68
Analysts Strong Buy
Price Target 34.50 (+1,454.05%)
Earnings Date Nov 14, 2024

About HOOK

HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company’s lead infectious disease product candidate is HB-200 for the treatment of pembrolizumab which is in Phase 2 of clinical trial; HB-700, a preclinical development for treatment of KRAS mutated cancers, including lung, colorectal, and pancreatic cancers. Its lead product candidates are HB-400 for the treatment of Hepatitis B which is in Phase I of clinical ... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Apr 18, 2019
Employees 179
Stock Exchange NASDAQ
Ticker Symbol HOOK
Full Company Profile

Financial Performance

In 2023, HOOKIPA Pharma's revenue was $20.13 million, an increase of 41.27% compared to the previous year's $14.25 million. Losses were -$81.58 million, 25.7% more than in 2022.

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for HOOK stock is "Strong Buy." The 12-month stock price forecast is $34.5, which is an increase of 1,454.05% from the latest price.

Price Target
$34.5
(1,454.05% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

HOOKIPA Pharma's Eseba-vec Highlighted in SITC Late-Breaker

Phase 2 trial evaluating eseba-vec/pembrolizumab combination resulted in a 52% ORR in PD-L1 CPS>20 patients and encouraging PFS and OS data, supported by highly durable and tumor-specific T cell respo...

4 weeks ago - GlobeNewsWire

HOOKIPA Pharma to Present Eseba-vec Combo in Frontline HNSCC as a Late-Breaker Poster Presentation at SITC 2024

Society of Immunotherapy of Cancer (SITC) poster to be presented by collaborator from Memorial Sloan Kettering Cancer Center, Dr. Alan Ho, on November 9, 2024 Society of Immunotherapy of Cancer (SITC)...

6 weeks ago - GlobeNewsWire

HOOKIPA Pharma Doses First Patients with Eseba-vec as Adjuvant Therapy in Phase 2 Investigator Lead Trial for Head & Neck Cancer

Study done in collaboration with Memorial Sloan Kettering and led by Dr. Winston Wong, Head and Neck Oncologist and Dr. Alan Ho, Chief of the Head and Neck Oncology Service

6 weeks ago - GlobeNewsWire

HOOKIPA Pharma to Present Strong Preclinical HB-700 Dataset

Preclinical proof-of-concept package to be presented at Industry Summit on RAS being held September 24-26, 2024 Preclinical proof-of-concept package to be presented at Industry Summit on RAS being hel...

2 months ago - GlobeNewsWire

Kaskela Law LLC Announces Shareholder Investigation of HOOKIPA Pharma Inc. (NASDAQ: HOOK) and Encourages Investors to Contact the Firm

PHILADELPHIA--(BUSINESS WIRE)--Kaskela Law LLC announces that it is investigating HOOKIPA Pharma Inc. (NASDAQ: HOOK) on behalf of the company's shareholders. Since May 2024, shares of HOOKIPA's stock ...

3 months ago - Business Wire

HOOKIPA Pharma Announces Board of Directors Changes

NEW YORK and VIENNA, Aug. 30, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK) (“HOOKIPA” or the “Company”), a company developing a new class of immunotherapeutics based on its proprietary ...

3 months ago - GlobeNewsWire

HOOKIPA Pharma to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

NEW YORK and VIENNA, Aug. 28, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, “HOOKIPA”, the “Company”), a company developing a new class of immunotherapeutics based on its proprietary are...

3 months ago - GlobeNewsWire

HOOKIPA Pharma Reports Second Quarter 2024 Financial Results and Recent Business Highlights

New Leadership Appointments; Positive Clinical and Regulatory Reports for the Lead Product Candidate, HB-200 (eseba-vec); On track to initiate the Phase 2/3 “AVALON-1” study with eseba-vec in Q4 2024

4 months ago - GlobeNewsWire

HOOKIPA Pharma Announces Leadership Changes to Intensify Focus on HB-200

NEW YORK and VIENNA, July 22, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK) (”HOOKIPA” or the “Company”), a company developing a new class of immunotherapeutics based on its proprietary ...

5 months ago - GlobeNewsWire

HOOKIPA Pharma Announces Effective Date of 1-for-10 Reverse Stock Split

NEW YORK and VIENNA, July 08, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, “HOOKIPA”), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platfor...

5 months ago - GlobeNewsWire

HOOKIPA Pharma Announces First Person Dosed in Phase 1b Clinical Trial of HB-500 for the Treatment of HIV

NEW YORK and VIENNA, July 01, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, HOOKIPA), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform,...

5 months ago - GlobeNewsWire

HOOKIPA Pharma Announces Updated Phase 2 Clinical Data at the American Society of Clinical Oncology 2024 Annual Meeting

NEW YORK and VIENNA, June 04, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platfor...

6 months ago - GlobeNewsWire

HOOKIPA Pharma to Host Investor Call on HB-200 Data Presented at American Society of Clinical Oncology 2024 Annual Meeting

NEW YORK and VIENNA, May 30, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, HOOKIPA or the Company), a company developing a new class of immunotherapeutics based on its proprietary arenav...

6 months ago - GlobeNewsWire

HOOKIPA Pharma Announces Positive Clinical Data to be Presented at the American Society for Clinical Oncology 2024 Annual Meeting

NEW YORK and VIENNA, May 23, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform...

7 months ago - GlobeNewsWire

HOOKIPA Pharma Reports First Quarter 2024 Financial Results and Recent Business Highlights

NEW YORK and VIENNA, May 09, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform...

7 months ago - GlobeNewsWire

HOOKIPA Pharma Announces Pivotal Phase 2/3 Trial Design for HB-200 in Combination with Pembrolizumab

NEW YORK and VIENNA, Austria, April 25, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, HOOKIPA or the Company), a company developing a new class of immunotherapeutics based on its proprie...

8 months ago - GlobeNewsWire

HOOKIPA Pharma Announces FDA Clearance of its Investigational New Drug Application for HB-700 for the Treatment of KRAS-Mutated Cancers

NEW YORK and VIENNA, Austria, April 24, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenavir...

8 months ago - GlobeNewsWire

Hookipa Pharma: 04/25/24 Update Should Be The First Of Several Positive Catalysts

Hookipa Pharma is conducting a call on 04/25/24 to share lead asset HB-200's pivotal trial design.  A Phase 2a clinical update is due in 2Q'24. The company's shares closed at $0.733, with a valuation ...

8 months ago - Seeking Alpha

HOOKIPA Pharma Announces Grant of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

NEW YORK and VIENNA, Austria, April 16, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenavir...

8 months ago - GlobeNewsWire

HOOKIPA Pharma to Host Investor Call on HB-200 and Planned Path to Registration

NEW YORK and VIENNA, Austria, April 10, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, HOOKIPA or the Company), a company developing a new class of immunotherapeutics based on its proprie...

8 months ago - GlobeNewsWire

HOOKIPA Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights

NEW YORK and VIENNA, Austria, March 22, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenavir...

9 months ago - GlobeNewsWire

HOOKIPA Pharma to Participate in Leerink Partners Global Biopharma Conference

NEW YORK and VIENNA, Austria, March 06, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenavir...

10 months ago - GlobeNewsWire

HOOKIPA Pharma Provides Update on Business Priorities and Oncology Partnership Programs

NEW YORK and VIENNA, Austria, Jan. 29, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenaviru...

11 months ago - GlobeNewsWire

HOOKIPA Pharma Appoints Mark Winderlich as Chief Development Officer to Lead Clinical Research and Development Organization

NEW YORK and VIENNA, Austria, Jan. 16, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenaviru...

11 months ago - GlobeNewsWire

HOOKIPA Pharma Announces $21.25 Million Equity Investment from Gilead Sciences

NEW YORK and VIENNA, Austria, Dec. 21, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenaviru...

1 year ago - GlobeNewsWire